AOTMiT: Transparency Council on ADHD and pediatric dentistry, among others

The agenda includes:

Preparation of positions on assessing the appropriateness of qualifying health care services as guaranteed benefits:

• "Preventive dental benefit for a child in the 3rd year of life",
• "Adaptive visit of the child in the 3rd and 4th year of life".

Preparation of an opinion on:

• The rationale for the introduction of prolonged-acting factor VIII within Module 4 of the health policy program entitled "National Program for the Treatment of Hemophilia and Related Hemorrhagic Diathesis Patients 2019-2023."
• The rationale for the introduction of prolonged-acting factor IX under Module 4 of the health policy program entitled "National Program for the Treatment of Hemophilia and Related Hemorrhagic Diathesis Patients for 2019-2023."

Preparation of a position paper on the legitimacy of granting approval for reimbursement of the medicinal product Elvanse (lisdexamfetamini dimesilas) for the indication: attention deficit hyperactivity disorder (ADHD) (ICD-10 F90.1.).

Source: AOTMiT